Stroke Clinical Trial
— NutristrokeOfficial title:
Influence of Nutritional Status on Rehabilitation Outcome in Subacute Stroke Patients
Verified date | September 2023 |
Source | Fondazione Don Carlo Gnocchi Onlus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Recently, is becoming more evident a relationship between malnutrition, stroke-related sarcopenia and/or altered systemic oxidative status in patients with subacute stroke . The aim of this study is the evaluation of nutritional status, the presence of stroke-related sarcopenia and systemic oxidative status in patients with subacute stroke outcomes; another aim is to investigate the correlation of nutritional status, the presence of stroke-related sarcopenia and systemic oxidative status on admission with the rehabilitative outcomes.
Status | Completed |
Enrollment | 119 |
Est. completion date | April 10, 2023 |
Est. primary completion date | April 10, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - stroke patients (hemorrhagic or ischemic) documented through Magnetic Resonance Imaging (MRI) or Computed Tomography (CT); - age between 18 and 85 years; - latency time within 6 months after the stroke event - sufficient cognitive and language skills to understand the instructions related to the administration of the assessment scales and to sign informed consent Exclusion Criteria: - presence of a previous stroke based on the medical history; - behavioral and cognitive disorders that may interfere with the therapeutic activity; - other orthopedic or neurological complications that may interfere with the rehabilitation protocol; - inability to understand and sign informed consent; - presence of pacemakers (for interference with bioimpedance measures). |
Country | Name | City | State |
---|---|---|---|
Italy | Don Gnocchi Foundation | Rome |
Lead Sponsor | Collaborator |
---|---|
Fondazione Don Carlo Gnocchi Onlus |
Italy,
Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, Compher C, Correia I, Higashiguchi T, Holst M, Jensen GL, Malone A, Muscaritoli M, Nyulasi I, Pirlich M, Rothenberg E, Schindler K, Schneider SM, de van der Schueren MA, Sieber C, Valentini L, Yu JC, Van Gossum A, Singer P. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017 Feb;36(1):49-64. doi: 10.1016/j.clnu.2016.09.004. Epub 2016 Sep 14. — View Citation
Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista G, Barazzoni R, Blaauw R, Coats A, Crivelli A, Evans DC, Gramlich L, Fuchs-Tarlovsky V, Keller H, Llido L, Malone A, Mogensen KM, Morley JE, Muscaritoli M, Nyulasi I, Pirlich M, Pisprasert V, de van der Schueren MAE, Siltharm S, Singer P, Tappenden K, Velasco N, Waitzberg D, Yamwong P, Yu J, Van Gossum A, Compher C; GLIM Core Leadership Committee; GLIM Working Group. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr. 2019 Feb;38(1):1-9. doi: 10.1016/j.clnu.2018.08.002. Epub 2018 Sep 3. — View Citation
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13. — View Citation
Fulle S, Protasi F, Di Tano G, Pietrangelo T, Beltramin A, Boncompagni S, Vecchiet L, Fano G. The contribution of reactive oxygen species to sarcopenia and muscle ageing. Exp Gerontol. 2004 Jan;39(1):17-24. doi: 10.1016/j.exger.2003.09.012. — View Citation
Knops M, Werner CG, Scherbakov N, Fiebach J, Dreier JP, Meisel A, Heuschmann PU, Jungehulsing GJ, von Haehling S, Dirnagl U, Anker SD, Doehner W. Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS). J Cachexia Sarcopenia Muscle. 2013 Sep;4(3):199-207. doi: 10.1007/s13539-013-0103-0. Epub 2013 Mar 13. — View Citation
Lelli D, Perez Bazan LM, Calle Egusquiza A, Onder G, Morandi A, Ortolani E, Mesas Cervilla M, Pedone C, Inzitari M. 25(OH) vitamin D and functional outcomes in older adults admitted to rehabilitation units: the safari study. Osteoporos Int. 2019 Apr;30(4):887-895. doi: 10.1007/s00198-019-04845-7. Epub 2019 Jan 16. — View Citation
Matsushita T, Nishioka S, Taguchi S, Yamanouchi A. Sarcopenia as a predictor of activities of daily living capability in stroke patients undergoing rehabilitation. Geriatr Gerontol Int. 2019 Nov;19(11):1124-1128. doi: 10.1111/ggi.13780. Epub 2019 Oct 7. — View Citation
Santoro M, Siotto M, Germanotta M, Bray E, Mastrorosa A, Galli C, Papadopoulou D, Aprile I. BDNF rs6265 Polymorphism and Its Methylation in Patients with Stroke Undergoing Rehabilitation. Int J Mol Sci. 2020 Nov 10;21(22):8438. doi: 10.3390/ijms21228438. — View Citation
Scherbakov N, Sandek A, Doehner W. Stroke-related sarcopenia: specific characteristics. J Am Med Dir Assoc. 2015 Apr;16(4):272-6. doi: 10.1016/j.jamda.2014.12.007. Epub 2015 Feb 10. — View Citation
Siotto, M., Germanotta, M., Santoro, M., Di Blasi, C., Loreti, C., Mastropaolo, S. & Aprile, I.,Total serum calcium and recovery after rehabilitation in patients with stroke Nov 1 2020, In : Applied Sciences (Switzerland). 10, 21, p. 1-8 8 p., 7893.
Squitti R, Siotto M, Assenza G, Giannantoni NM, Rongioletti M, Zappasodi F, Tecchio F. Prognostic Value of Serum Copper for Post-Stroke Clinical Recovery: A Pilot Study. Front Neurol. 2018 May 30;9:333. doi: 10.3389/fneur.2018.00333. eCollection 2018. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change in Mini nutritional Assessment (MNA) scores | it is a questionnaire that evaluates the nutritional status | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in Body Mass Index | it is a measure of body fat based on height and weight that applies to adult men and women expressed in kg/m² | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | weight change | detection of the weight drop or weight increase | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in food income detection | detection of food intake by measurement of portion of dish assumed from the patients | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in Bioimpedance analysis (BIA) measurements | it is a non-invasive measurement of body fat, lean muscle mass and hydration | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in hand grip strenght test score | it is a test to measure the maximum isometric strenght of the hand and forearm muscles | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in Time Up & Go test (TUG) scores | The Time Up And Go is a test used to assess mobility, balance, and walking in people with balance impairments. The subject must stand up from a chair (which should not be leant against a wall), walk a distance of 3 meters, turn around, walk back to the chair and sit down - all performed as quickly and as safely as possible. Time will be measured using a chronometer. | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in Barthel index (BI) scores | The BI is designed to assess the ability of an individual with a neuromuscular or musculoskeletal disorder to care for him/herself. It ranges from 0 to 100, with a higher number meaning better performance in activities of daily living. | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in Fugl-Meyer Assessment of Motor Recovery after Stroke for Upper Extremity portion (FMA-UL) scores | The FMA-UL is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, sensation and joint functioning in patients with post-stroke hemiplegia. The upper limb portion of the FMA-UL ranges from 0 (hemiplegia) to 66 points (normal upper limb motor performance) | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in Motricity Index (MI) scores | The MI aims to evaluate lower limb motor impairment after stroke, administrated on both sides. Items to assess the lower limbs are 3, scoring from 0 to 33 each: (1) ankle dorsiflexion with foot in a plantar flexed position (2) knee extension with the foot unsupported and the knee at 90° (3) hip flexion with the hip at 90° moving the knee as close as possible to the chin. (no movement: 0, palpable flicker but no movement: 9, movement but not against gravity :14, movement against gravity movement against gravity: 19, movement against resistance: 25, normal:33). |
Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in Numerical Rating Scale (NRS) scores | The Numeric Rating Scale (NRS) is the simplest and most commonly used numeric scale to rate the pain from 0 (no pain) to 10 (worst pain). | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in Neuropathic Pain Four Questions (DN4) scores | The DN4 used to evaluate presence of neuropathic pain, and consist of a brief interview of four questions answered yes/no: two on what the patient has conceived and two during the exam for the evaluation of hypoesthesia to the touch or sting and the evaluation of allodynia with the skimming of the skin. For each 'yes' a point is assigned. The total score is given by the sum of the individuals. The cut off for the presence of neuropathic pain is '4'. | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in Modified Ashworth Scale (MAS) scores | The MAS is a 6 point ordinal scale used for grading hypertonia in individuals with neurological diagnoses. A score of 0 on the scale indicates no increase in tone while a score of 4 indicates rigidity. Tone is scored by passively moving the individual's limb and assessing the amount of resistance to movement felt by the examiner. | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in 10 Meter Walk Test scores | This test will assess the patient's speed during gait. Patients will be asked to walk at their preferred maximum and safe speed. Patients will be positioned 1 meter before the start line and instructed to walk 10 meters, and pass the end line approximately 1 meter after. The distance before and after the course are meant to minimize the effect of acceleration and deceleration. Time will be measured using a stopwatch and recorded to the one hundred of a second (ex: 2.15 s). The test will be recorded 3 times, with adequate rests between them. The average of the 3 times should be recorded. | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in Six-Minute Walking Test (6MWT) scores | The 6MWT measures the distance a subject covers during an indoor gait on a flat, hard surface in 6 minutes, using assistive devices, as necessary. The test is a reliable and valid evaluation of functional exercise capacity and is used as a sub-maximal test of aerobic capacity and endurance. The minimal detectable change in distance for people with sub-acute stroke is 60.98 meters. The 6MWT is a patient self-paced walk test and assesses the level of functional capacity. Patients are allowed to stop and rest during the test. However, the timer does not stop. If the patient is unable to complete the test, the time is stopped at that moment. The missing time and the reason of the stop are recorded. This test will be administered while wearing a pulse oximeter to monitor heart rate and oxygen saturation, also integrated with Borg scale to assess dyspnea. | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in blood levels of systemic oxidative stress (dROMs) | dROMs test measures circulating hydroperoxides (UCarr) | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in antioxydant capacity of serum (BAP) | BAP test measures total antioxidant status in serum in micromol/L | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in thiol serum levels (SHp) | SHp test measures the circulating thiolic antioxidants in serum in micromol/L | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change haemoglobin serum levels | serum measurements of haemoglobin g/dL | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in glucose serum levels | serum measurements of glucose in mg/dL | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in albumine serum levels | serum measurements of glucose in g/dL | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in triglycerides serum levels | serum measurements of triglycerides in mg/dL | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in total cholesterol serum levels | serum measurements of total cholesterol in mg/dL | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in HDL cholesterol serum levels | serum measurements of HDL cholesterol in mg/dL | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in calcium serum levels | serum measurements of calcium in mg/dL | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in magnesium serum levels | serum measurements of magnesium in mg/dL | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in creatinin serum levels | serum measurements of creatinin in mg/dL | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in iron serum levels | serum measurements of iron in microg/dL | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in latent iron binding capacity serum levels | serum measurements of latent iron binding capacity in microg/dL | Baseline (T0), Treatment (6 weeks) (T1) | |
Primary | change in hepatic status serum levels (ALT-GPT) | serum measurements o ALT-GPT in U/L | Baseline (T0), Treatment (6 weeks) (T1) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04101695 -
Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects
|
N/A | |
Completed |
NCT04034069 -
Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial
|
N/A | |
Suspended |
NCT03869138 -
Alternative Therapies for Improving Physical Function in Individuals With Stroke
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Completed |
NCT00391378 -
Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)
|
N/A | |
Recruiting |
NCT06204744 -
Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial
|
N/A | |
Active, not recruiting |
NCT06043167 -
Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
|
||
Enrolling by invitation |
NCT04535479 -
Dry Needling for Spasticity in Stroke
|
N/A | |
Completed |
NCT03985761 -
Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke
|
N/A | |
Recruiting |
NCT00859885 -
International PFO Consortium
|
N/A | |
Recruiting |
NCT06034119 -
Effects of Voluntary Adjustments During Walking in Participants Post-stroke
|
N/A | |
Completed |
NCT03622411 -
Tablet-based Aphasia Therapy in the Chronic Phase
|
N/A | |
Completed |
NCT01662960 -
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
|
N/A | |
Recruiting |
NCT05854485 -
Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke
|
N/A | |
Active, not recruiting |
NCT05520528 -
Impact of Group Participation on Adults With Aphasia
|
N/A | |
Active, not recruiting |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Completed |
NCT05805748 -
Serious Game Therapy in Neglect Patients
|
N/A | |
Recruiting |
NCT05621980 -
Finger Movement Training After Stroke
|
N/A |